NASDAQ · AXGN
Axogen, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarThe next earnings date for AXGN has not been announced yet.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Dec 2026 | $-0.03 | $-0.01 | $-0.04 | 2 |
| Mar 2027 | $0.02 | $0.04 | $0.00 | 2 |
| Jun 2027 | $0.00 | $0.01 | $-0.01 | 2 |
| Sep 2027 | $0.03 | $0.04 | $0.02 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · MarketBeat · BNK Invest · RTTNews- Zacks · Oct 29, 8:40 AM EDTIs AxoGen (AXGN) Outperforming Other Medical Stocks This Year?Here is how AxoGen (AXGN) and BioCryst Pharmaceuticals (BCRX) have performed compared to their sector so far this year.
- MarketBeat · Oct 28, 6:04 PM EDTAxoGen Q3 Earnings Call Highlights3 Emerging Biotech Stocks With Significant Upside PotentialAxoGen (NASDAQ:AXGN) reported third-quarter revenue growth of 26.2% as demand for its nerve-repair products increased across its breast, extremities, oral and maxillofacial, and head-and-neck markets. The company also rai
- BNK Invest · Oct 28, 3:24 PM EDTNoteworthy Wednesday Option Activity: SPCX, AXGN, GFLLooking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Space Exploration Technologies Corp (Symbol: SPCX), where a total volume of 1.1 million contracts has been traded thus far today, a contract volume which is repr
- RTTNews · Oct 28, 3:16 PM EDTBiotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%(RTTNews) – Shares of several biotech companies moved higher following quarterly financial results, clinical trial developments and business updates. Genmab reported positive Phase 3 results for its cancer drug combination, Pulmonx posted improved quarterly results, Axogen and Or
- The Motley Fool · Oct 28, 2:28 PM EDTAxogen (AXGN) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Fintel · Oct 28, 11:52 AM EDTAxogen, Inc. Reports Third Quarter 2026 Financial Results and Raises Full Year Revenue Guidance to at Least 29% Growth or $290 millionAxogen, Inc. reported its financial results for the third quarter ended September 30, 2026. Revenue for the quarter was $75.8 million, an increase of 26.2% compared to $60.1 million in the third quarter of 2025. Net income was $2.3 million, or $0.04 per share, compared to $0.7 mi
- RTTNews · Oct 28, 7:37 AM EDTAxoGen, Inc. Reports Advance In Q3 Bottom Line(RTTNews) – AxoGen, Inc. (AXGN) reported earnings for its third quarter that Increases, from last year
- Zacks · Oct 28, 7:35 AM EDTAxoGen (AXGN) Beats Q3 Earnings and Revenue EstimatesAxoGen (AXGN) delivered earnings and revenue surprises of +50.00% and +4.17%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Oct 21, 9:00 AM EDTAxoGen (AXGN) Reports Next Week: Wall Street Expects Earnings GrowthAxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 16, 10:40 AM EDTGMED or AXGN: Which Is the Better Value Stock Right Now?GMED vs. AXGN: Which Stock Is the Better Value Option?
- Zacks · Oct 13, 12:41 PM EDTHere's Why You Should Retain DexCom Stock in Your Portfolio for NowDexCom's strong margins, G7 15-day rollout and promising pipeline support its growth outlook, but factory ramp-up costs, forex and input-price pressures pose risks.
- Fintel · Oct 7, 4:06 PM EDTBarclays Initiates Coverage of Axogen with Overweight RatingFintel reports that on October 7, 2026, Barclays initiated coverage of Axogen (NASDAQCM:AXGN) (LSE:0HKD) with a Overweight recommendation. AxoGen, Inc., based in the United States, operates primarily in the healthcare sector, focusing on the development and commercialization of t
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Axogen, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.